Back to top
more

Sage Therapeutics (SAGE)

(Delayed Data from NSDQ)

$8.41 USD

8.41
524,997

+0.22 (2.69%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%

by Zacks Equity Research

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.44% and 69.89%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag

by Sundeep Ganoria

The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.

Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.

Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why

by Zacks Equity Research

The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.

Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News

by Zacks Equity Research

Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.

Company News for Aug 8, 2023

by Zacks Equity Research

Companies in The News Are: KKR,SAGE,VTRS,FRPT

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -5.93% and 15.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far

by Zacks Equity Research

Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

by Zacks Equity Research

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.

Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sage and Biogen's NDA for Depression Drug Gets Priority Review

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.

Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB

by Zacks Equity Research

XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.

Andrew Rocco headshot

Biotech's Blockbuster Week: 3 Stocks to Watch

by Andrew Rocco

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage

by Zacks Equity Research

ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.

Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

by Zacks Equity Research

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

by Andrew Rocco

Atai, Biogen, and Sage are working to develop new treatments for mental illness.